Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-079 in Generalized Myasthenia Gravis
NCT04159805Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of mezagitamab in myasthenia gravis (MG), sponsored by Takeda. Started Jan 2020; status: completed.
02
Drugs
mezagitamab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04159805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159805.